Daiichi alleged that Singh brothers had concealed and misrepresented critical information concerning US Food and Drug Administration and Department of Justice investigations into Ranbaxy
In 2014, Sun Pharma agreed to buy Ranbaxy -- which was then controlled by Daiichi.
NHAI to pull plug on Rs 3,000-crore ventures for poor show
Sanjeev Vashishta, chief executive officer at SRL Diagnostics, talks to Deepak Patel about expansion plans and regulations for the sector.
Govt bans brands with annual sales worth Rs 3,728 crore.
Between 2011 and 2014, they indirectly determined the price of tyres in the market, says report
Lobby group tells USTR it has got assurance from India on compulsory licensing.
A dialysis machine contributes only 6 per cent to the overall cost.
11 states were assessed for access to clean water, energy and sanitation and use of iodised salt.
The impact from NELM on the Indian pharmaceutical sector is estimated to be around Rs 6,000 crore.
The French drug maker has its vaccine approved in Mexico for all four serotypes for patients aged 9 to 45.
The BSE fined 370 listed companies following the Sebi notification.
RINL wiped out its losses in 2005-06 with money from the government.
Currently there is no standard ideal debt to equity ratio.
The 2015 World Bank group's Doing Business index ranked India at 142, down from 140, which it was the year before.
A key government official involved in initiatives to make doing business in the country easier said improving the ranking to 50th in a year was not possible but the country could certainly do that over two years.
Companies that are listed or are in the process of being listed, and have a net worth of at least Rs 500 crore, must adopt these standards from April 1, 2016.
The move is aimed at making it easier to do business in India.
Zopper, a price comparison site, with 2,000 online and 200,000 offline merchants on board, aims to increase user activity 100 times in 3 years.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances